FindTrial
Sign In

Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis

Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-000397-71-DK
Enrollment
30
Registered
2006-05-02
Start date
2006-05-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Keppra Product Name: Levetiracetam Product Code: ucb L059 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Sponsors

Søren H. Sindrup, Department of Neurology, Odense University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.The diagnoses multiple sclerosis verified by neurologist 2.age over 18 years 3.neuropathic pain which for at least 3 months and had its onset at least 6 months after the diagnoses multiple sclerosis had been verified 4.average baseline pain score of at least 4 on a 0 to 10 numeric rating scale 5.informed consent Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1.additional cause of pain 2.allergic reactions towards levettiracetam 3.pregnancy or beast feeding period 4.severe illness 5.lack of ability to follow study protocol 6.treatment with antidepressants, anticonvulsants or opioids

Design outcomes

Primary

MeasureTime frame
Main Objective: To determine if levetiracetam will relieve central neuropathic pain in multiple sclerosis ;Secondary Objective: In patients with central neuropathic pain in multiple sclerosis to determine the effect of levetiracetam 1- specific pain symptoms 2-on quality of life 3-pain related sleep disturbance 4-on spasticity ;Primary end point(s): Patients verbal score of pain relief (complete, good, moderate, slight, no, worse) at the end of each treatment period—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026